That will be the game changer, and badly needed. The game changer will not be the course of action we seem to be headed on. There is talk of full income replacement of up to $80,000. National sacrifice is necessary, not, Carry on with your usual frivolous lifestyle and we'll just borrow infinite money to support that.
| Vaccine | Comments |
|---|---|
| INO-4800 (Inovio Pharmaceuticals) [61] | Phase 1 human clinical trials are expected to begin in April 2020. In addition, Inovio has received a grant from the Bill and Melinda Gates Foundation to accelerate testing and scale up a smart device (Cellectra 3PSP) for large-scale intradermal vaccine delivery. |
| mRNA-1273 (Moderna Inc) [62] | A phase 1 study has been initiated in 45 healthy volunteers as of March 16, 2020 at Kaiser Permanente Washington Health Research Instituted in Seattle. |
| mRNA vaccine (CureVac) [63] | Vaccine is in development and not yet ready for human testing as of March 16, 2020. |
| COVID-19 S-Trimer (GlaxoSmithKline [GSK] and Clover Biopharmaceuticals) [64] | Preclinical development is underway using GSK’s adjuvants (compounds that enhance vaccine efficacy) and Clover’s proprietary proteins, which stimulate an immune response. |
| SARS-CoV-2 vaccine (Johnson & Johnson [J&J]) [65] | Partnering with the Biomedical advanced Research and Development Authority (BARDA) to utilize Janssen’s AdVac and PER.C6 technologies, which provide rapid upscale production of an optimal vaccine candidate. |
| rDNA vaccine (Sanofi) [66] | Collaborating with BARDA to develop a vaccine using their recombinant DNA platform. |
| Saponin-based Matrix-M adjuvant vaccine (Novavax) [67] | Stimulates the entry of antigen-presenting cell into the injection site and enhances antigen presentation in local lymph nodes to boost the immune response. |
| Live-attenuated vaccine (Codagenix) [68] | Codagenix, a clinical-stage biotechnology company, is collaborating with the Serum Institute of India to co-develop a live-attenuated vaccine. |
| PCR-based DNA vaccine (Applied DNA Sciences and Takis Biotech) [69] | The collaboration has designed four COVID-19 vaccine candidates utilizing PCR-based DNA manufacturing systems for preclinical testing in animals. |
| Intranasal COVID-19 vaccine (Altimmune, Inc) [70] | Design and synthesis has been completed and is advancing toward animal testing. |
Extremely wealthy on top of a pile of skulls. The hallmark of capitalism.
Two Women Fell Sick From the Coronavirus. One Survived. (Published 2020)
The young medical professionals came down with fevers. Within weeks, they were both lying in hospital beds, hooked up to IVs or oxygen machines.www.nytimes.com
China used all sorts of drugs. A shotgun approach. With 80,000 infected they haven't been able to show any significant difference.
Two Women Fell Sick From the Coronavirus. One Survived. (Published 2020)
The young medical professionals came down with fevers. Within weeks, they were both lying in hospital beds, hooked up to IVs or oxygen machines.
China used all sorts of drugs. A shotgun approach. With 80,000 infected they haven't been able to show any significant difference.
It's pretty warm and humid in Brazil, some of Australia, Indonesia, Thailand, and the UAE ...
While the data have not yet been published, and should therefore be interpreted with caution, this non-randomised, unblinded study showed a strong reduction in viral load with hydroxychloroquine.
After 6 days, the percentage of patients testing positive for COVID-19 who received hydroxychloroquine fell to 25% versus 90% for those who did not receive the treatment (a group of untreated COVID-19 patients from Nice and Avignon).
In addition, comparing untreated patients, those receiving hydroxychloroquine and those given hydroxychloroquine plus the antibiotic azithromycin, the results showed there was "a spectacular reduction in the number of positive cases" with the combination therapy, said Prof Raoult.
At 6 days, among patients given combination therapy, the percentage of cases still carrying SRAS-CoV-2 was no more than 5%.
Azithromycin was added because it is known to be effective against complications from bacterial lung disease but also because it has been shown to be effective in the laboratory against a large number of viruses, the infectious disease specialist explained.
"Everyone who died from COVID-19 were still carriers of coronavirus. To no longer have the virus changes the prognosis," Prof Raoult said.
COVID-19: Could Hydroxychloroquine Really Be the Answer?
Repurposing an old malaria drug to treat patients with COVID-19 could not only reduce symptoms and shorten the disease duration but also reduce the viral load, suggests a preliminary French study.www.medscape.com
www.google.com
So does it reduce mortality? I would bet it doesn't, as in it "works" in people who would survive anyway. I have a feeling this will turn out to be a pile of garbage, as in NSAIDs may have the same effect.While the data have not yet been published, and should therefore be interpreted with caution, this non-randomised, unblinded study showed a strong reduction in viral load with hydroxychloroquine.
After 6 days, the percentage of patients testing positive for COVID-19 who received hydroxychloroquine fell to 25% versus 90% for those who did not receive the treatment (a group of untreated COVID-19 patients from Nice and Avignon).
In addition, comparing untreated patients, those receiving hydroxychloroquine and those given hydroxychloroquine plus the antibiotic azithromycin, the results showed there was "a spectacular reduction in the number of positive cases" with the combination therapy, said Prof Raoult.
At 6 days, among patients given combination therapy, the percentage of cases still carrying SRAS-CoV-2 was no more than 5%.
Azithromycin was added because it is known to be effective against complications from bacterial lung disease but also because it has been shown to be effective in the laboratory against a large number of viruses, the infectious disease specialist explained.
"Everyone who died from COVID-19 were still carriers of coronavirus. To no longer have the virus changes the prognosis," Prof Raoult said.
COVID-19: Could Hydroxychloroquine Really Be the Answer?
Repurposing an old malaria drug to treat patients with COVID-19 could not only reduce symptoms and shorten the disease duration but also reduce the viral load, suggests a preliminary French study.www.medscape.com
The CEO of the buzzy biotech that's working on a potential coronavirus vaccine just pledged he won't set a high price for the shot
The CEO of the buzzy biotech that's working on a potential coronavirus vaccine just pledged he won't set a high price for the shot
Moderna CEO Stephane Bancel said the company will be "extremely thoughtful and sensitive" in determining a price if its experimental vaccine works.
My point exactly.
The latter, clearly. ICUs don't make as much money as ORs, quite the opposite.
I wouldn't advertise having it. because you could have only bought it ilegally. As in you don't have an indication for it.
Kaletra pilot study in NEJM was a colossal flop today.
How surprising.
Dude, we don’t even have enough test kits MONTHS into this mess (unless you are a celebrity or NBA star). A vaccine or cure mass produced for all is a long, LONG time away... I think Tom Hanks and Idris Elba will have access long before you or I do.
